ArriVent BioPharma, Inc. (AVBP) vs Prime Medicine, Inc. (PRME)
A side-by-side comparison of ArriVent BioPharma, Inc. and Prime Medicine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PRME
Prime Medicine, Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AVBP vs PRME
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)PRME -50.8% (-21.1%/yr)AVBP compounded faster over this window
AVBP PRME
AVBP vs PRME: by the numbers
- •AVBP is the larger company ($703M vs $632M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -4613.11% net margin).
Metrics side by side
Valuation
| Metric | AVBP | PRME |
|---|---|---|
| P/S ratio | N/A | 155.21 |
| P/B ratio | 1.92 | 15.88 |
Profitability
| Metric | AVBP | PRME |
|---|---|---|
| Gross margin | 0.00% | -58.05% |
| Operating margin | 0.00% | -4498.06% |
| Net margin | 0.00% | -4613.11% |
| ROE | -44.63% | -471.98% |
| ROIC | -47.96% | -90.42% |
Growth (annualized)
| Metric | AVBP | PRME |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -2.32% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.